E. Bargagli (Siena, Italy), M. Garcia Moyano (Barakaldo, Spain)
Ultrasound may detect subclinical interstitial lung disease in systemic sclerosis
M. Gutierrez (Mexico City, Mexico), C. Bertolazzi (Mexico City, Mexico), D. Clavijo-Cornejo (Mexico City, Mexico), F. Salaffi (Jesi, Italy)
|  |
Progressive interstitial lung disease is frequent also in late disease stages in systemic sclerosis patients from EUSTAR
A. Hoffmann-Vold (Oslo, Norway), C. Brunborg (Oslo, Norway), P. Airò (Brescia, Italy), L. Ananyeva (Moscow, Russian Federation), L. Czirják (Pécs, Hungary), S. Guiducci (Florence, Italy), E. Hachulla (Lille, France), M. Li (Peking, China), C. Mihai (Zurich, Switzerland), G. Riemekasten (Lübeck, Germany), P. Sfikakis (Athens, Greece), G. Valentini (Napoli, Italy), O. Kowal-Bielecka (Bialystok, Poland), Y. Allanore (Paris, France), O. Distler (Zurich, Switzerland)
|  |
Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study
S. Lettieri (Pavia, Italy), E. Bozzalla-Cassione (Pavia, Italy), G. Zanframundo (Pavia, Italy), V. Vertui (Pavia, Italy), M. Della Zoppa (Pavia, Italy), V. Chino (Pavia, Italy), F. Bertuccio (Pavia, Italy), L. Cavagna (Pavia, Italy), F. Meloni (Pavia, Italy)
| |
Radiological Patterns and Pulmonary Function Value of Lung Involvement in Primary Sjögren’s Syndrome
C. Candia (Napoli (NA), Italy), R. Rega (Napoli (NA), Italy), I. Mormile (Napoli (NA), Italy), M. Williams (Napoli (NA), Italy), E. Sferra (Napoli (NA), Italy), A. De Paulis (Napoli (NA), Italy), F. Rossi (Napoli (NA), Italy), A. Molino (Napoli (NA), Italy)
| |
Adherence to daily home-based spirometry during a 3-month period in patients with ILD: The RALPMH Study
M. Althobiani (London, United Kingdom), Y. Ranjan (London, United Kingdom), J. Jacob (London, United Kingdom), M. Orini (London, United Kingdom), R. Dobson (London, United Kingdom), J. Hurst (London, United Kingdom), J. Porter (London, United Kingdom), A. Folarin (London, United Kingdom)
| |
Gratitude perception during Mindfulness-Based Intervention (IBM) in patients with interstitial lung disease (ILD)
E. Viana Mancuzo (Belo Horizonte (MG), Brazil), S. Duarte Miranda (Belo Horizonte (MG), Brazil), G. Assis Pires (Belo Horizonte (MG), Brazil), L. Ferreira Pereira (Belo Horizonte (MG), Brazil), A. Albuquerque Leal (Belo Horizonte (MG), Brazil), S. Cunha Paiva (Belo Horizonte (MG), Brazil)
| |
Progressive fibrosing interstitial lung disease in hypersensitivity pneumonitis
M. Alberti (Buenos Aires, Argentina), J. Malet Ruiz (Buenos Aires, Argentina), L. Fassola (Buenos Aires, Argentina), S. Auteri (Buenos Aires, Argentina), M. Fernandez (Buenos Aires, Argentina), P. Donati (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina)
| |
Baseline characteristics and survival of Progressive Fibrosing Interstitial Lung Disease in Rheumatoid Arthritis. A single center retrospective study.
F. Caro (Ciudad Autónoma Buenos Aires, Argentina), P. Donati (Ciudad Autónoma Buenos Aires, Argentina), R. Ruiz (Ciudad Autónoma Buenos Aires, Argentina), S. Auteri (Ciudad Autónoma Buenos Aires, Argentina), L. Fassola (Ciudad Autónoma Buenos Aires, Argentina), M. Fernández (Ciudad Autónoma Buenos Aires, Argentina), T. Barbich (Ciudad Autónoma Buenos Aires, Argentina), M. Alberti (Ciudad Autónoma Buenos Aires, Argentina)
| |
Effectiveness of immunosuppressive therapy in the progression of rheumatoid arthritis-associated interstitial lung disease in adult patients. A systematic review and meta analysis
M. Tapia (Santiago, Chile), J. Lopez (Santiago, Chile), L. Toro (Santiago, Chile), N. Ruiz (Santiago, Chile), M. Salinas (Santiago, Chile)
| |
Clinical outcomes of patients with acute exacerbations in interstitial lung diseases
M. Ramos Martins (Porto, Portugal), D. Barros-Coelho (Porto, Portugal), P. Ribeirinho-Soares (Porto, Portugal), A. Terras-Alexandre (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano-Mota (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Morais (Porto, Portugal)
| |
ILD associated with primary Sjögren’s syndrome is frequently progressive
A. Hoffmann-Vold (Oslo, Norway), H. Fretheim (Oslo, Norway), P. Diep (Oslo, Norway), K. Lerang (Oslo, Norway), H. Andersson (Oslo, Norway), Ø. Midtvedt (Oslo, Norway), T. Garen (Oslo, Norway), M. Durheim (Oslo, Norway), T. Aaløkken (Oslo, Norway), Ø. Palm (Oslo, Norway), Ø. Molberg (Oslo, Norway)
| |
Clinical difference of interstital lung disease patients positive for anti-amnioacyl-tRNA (ARS) synthetase antibodies between dermatomyositis/polymyositis (PM/DM) group and non-myosits group
M. Momose (Kurashiki, Japan), M. Arita (Kurashiki, Japan), T. Ishida (Kurashiki, Japan)
| |
PAD4 is associated with the predominance of fibrosis in interstitial lung diseases-rheumatoid arthritis
K. Nava Quiroz (México, Mexico), G. Pérez-Rubio (México, Mexico), I. Buendía-Roldán (México, Mexico), M. Mejía (México, Mexico), J. Rojas-Serrano (México, Mexico), P. Rodríguez-Henríquez (México, Mexico), R. Falfán-Valencia (México, Mexico)
| |
Estimating the addition clinical workload required for nintedinib treatment in PF-ILD
A. Livesey (Birmingham, United Kingdom), M. Duggal (Birmingham, United Kingdom), A. Crawshaw (Birmingham, United Kingdom), D. Dosanjh (Birmingham, United Kingdom), D. Thickett (Birmingham, United Kingdom)
| |
UK Pigeon Fanciers display a high prevalence of symptoms normally associated with connective tissue disease ILD
M. Spears (Perth, United Kingdom), L. Wain (Leicester, United Kingdom), B. Gooptu (Leicester, United Kingdom), S. Bourke (Newcastle, United Kingdom), M. Embley (Larbert, United Kingdom), P. Lynch (Larbert, United Kingdom), G. Boyd (Larbert, United Kingdom), C. Mcsharry (Glasgow, United Kingdom)
| |
Assessment of initial dyspnea predicts progression of systemic sclerosis-associated interstitial lung disease (ILD-SSc) at 5 years.
E. Viana Mancuzo (Belo Horizonte (MG), Brazil), L. Arreguy Nogueira (Belo Horizonte (MG), Brazil), R. Amorim Correa (Belo Horizonte (MG), Brazil), L. Ferreira Pereira (Belo Horizonte (MG), Brazil)
| |
Computed tomography morphometric analysis of idiopathic inflammatory myopathy related interstitial lung disease correlates with forced vital capacity
A. O'Mahony (Cork, Ireland), P. Henry (Cork, Ireland), P. Coghlan (Cork, Ireland), C. Crowley (Cork, Ireland), D. Ryan (Cork, Ireland), N. Moore (Cork, Ireland), M. Maher (Cork, Ireland), O. O'Connor (Cork, Ireland), M. Henry (Cork, Ireland)
| |
Profile of patients with Connective disease associated ILD presenting to a tertiary care hospital in South India
S. Christopher (Vellore, India), B. Isaac (Vellore, India), D. Christopher (Vellore, India), B. Thangakunam (Vellore, India)
| |
Evolution of fibrotic interstitial lung diseases (ILD) after COVID-19
M. Ramos Martins (Porto, Portugal), M. Serino (Porto, Portugal), B. Martins (Porto, Portugal), I. Carvalho (Porto, Portugal), C. Valente (Porto, Portugal), M. Barbosa (Porto, Portugal), C. Cascais-Costa (Porto, Portugal), M. Alves (Porto, Portugal), A. Terras-Alexandre (Porto, Portugal), N. Melo (Porto, Portugal), P. Caetano-Mota (Porto, Portugal), H. Novais-Bastos (Porto, Portugal), A. Morais (Porto, Portugal)
| |
Progressive Idiopathic Inflammatory Myopathy-associated Interstitial Lung Diseases (IIM-ILDs)
E. Cocconcelli (Padova (PD), Italy), E. Zanatta (Padova (PD), Italy), C. Giraudo (Padova (PD), Italy), G. Castelli (Padova (PD), Italy), N. Bernardinello (Padova (PD), Italy), G. Fiorentù (Padova (PD), Italy), C. Dartora (Padova (PD), Italy), L. Iaccarino (Padova (PD), Italy), P. Spagnolo (Padova (PD), Italy), E. Balestro (Padova (PD), Italy)
| |